Plasminogen Activator Type 1 (Af Epitope) antibody
-
- Target
- Plasminogen Activator Type 1
- Binding Specificity
- Af Epitope
- Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- Un-conjugated
- Application
- Immunoassay (IA), Inhibition Assay (InhA)
- Sterility
- 0.2 μm filtered
- Clone
- MA-55F4C12
-
-
- Application Notes
- For inhibition of biological activity dilutions have to be made according to the amounts PAI-1 to be inactivated.
- Restrictions
- For Research Use only
-
- Buffer
- PBS, containing 0.1 % bovine serum albumin.
- Storage
- 4 °C
- Storage Comment
- Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.
- Expiry Date
- 12 months
-
-
Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition." in: Thrombosis and haemostasis, Vol. 90, Issue 1, pp. 52-8, (2003) (PubMed).
: "Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms." in: Biochimica et biophysica acta, Vol. 1337, Issue 2, pp. 257-66, (1997) (PubMed).
: "
-
Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition." in: Thrombosis and haemostasis, Vol. 90, Issue 1, pp. 52-8, (2003) (PubMed).
-
- Target
- Plasminogen Activator Type 1
- Background
- Plasminogen activator inhibitor type-1 (PAI-1), a member of the serine protease inhibitor (serpin) superfamily is an important protein in the regulation of fibrinolysis. PAI-1 is unique among the serpins because of its functional and conformational flexibility. PAI-1 is the most important physiological inhibitor of both tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA). Increased PAI-1 levels are associated with thrombotic events and is an established risk factor for cardiovascular diseases. The active conformation PAI-1 inhibits its target proteinases by the formation of a stable, inactive complex. Although PAI-1 is synthesized as an active molecule, it converts spontaneously to an inactive, latent form that can be partially reactivated by denaturing agents. In addition, a third conformation reacting as a non-inhibitory substrate towards various target proteinases has been identified. The epitope of monoclonal antibody MA-55F4C12 is within the stretch of 29 amino acids in PAI-1 (region Glu128-Ala131). Glu128, Val129, Glu130, Arg131 and Lys154 are the major determinants. All five residues act cooperatively in the binding to MA-55F4C12 and constitute the epitope. The epitope of the antibody does not cover the complete alpha-helix F and turn connecting alpha-helix F and beta-strand s3A, but is restricted to the hinge region between alpha-helix F and the main part of the PAI-1 Molecule. The monoclonal antibody MA-55F4C12 is a 'switching' antibody, capable of inducing a non-inhibitory substrate form of PAI-1. The antibody cross reacts with rat and mouse PAI-1.
-